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Abstract
The use of chemotherapeutics as a possible treatment strategy in avian oncology is steadily
increasing over the last years. Despite this, literature reports regarding dosing strategies
and pharmacokinetic behaviour of chemotherapeutics in avian species are lacking. The aim
of the present study was to investigate the pharmacokinetics of carboplatin in a representa-
tive species of the order ofGalliformes, Anseriformes, Columbiformes and Psittaciformes.
Eight chickens, ducks and pigeons and twenty-eight parakeets were administered carbo-
platin intravenously (5 mg/kg body weight). A specific and sensitive liquid chromatography-
tandem mass spectrometry method was developed and validated for quantification of the
free carboplatin in plasma of the four birds species (limit of quantification: 20 ng/mL for
chicken and duck, 50 ng/mL for pigeon and 100 ng/mL for parakeets). Non-compartmental
pharmacokinetic analysis and allometric scaling demonstrated a significant correlation (R² =
0.9769) between body weight (BW) and elimination half-life (T1/2el). T1/2el ranged from 0.41
h in parakeets (BW: 61 ± 8 g) to 1.16 h chickens (BW: 1909 ± 619 g). T1/2el is a good param-
eter for dose optimization of carboplatin in other avian species, since also the previously
reported T1/2el in cockatoos (average BW: 769 ± 68 g) of 1.00 h corresponds to the results
obtained in the present study.
Introduction
Neoplastic diseases are frequently reported in commonly kept pet birds of the order of Galli-
formes, Anseriformes, Columbiformes and Psittaciformes [1–5]. The use of chemotherapeutics
as a possible treatment strategy in avian oncology is steadily increasing over the last years [6].
Defining the optimal treatment protocol for tumours in birds, however is still largely empirical.
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Treatment protocols used in birds have been extrapolated from other companion animals such
as dogs and cats or humans [7]. As uro-genital and integumentary neoplastic processes are
amongst the most common tumours in birds [1, 2, 5], the use of platinum-based antineoplastic
agents is of great interest. Carboplatin [cis-diammine (1,1-cyclobutanedicarboxylato) platinum
(II)] (CPT) is a water-soluble second generation platinum compound used to treat ovarian and
cervix carcinomas and bladder cancers in humans. Carboplatin was developed to reduce
adverse effects such as myelosuppression, nephrotoxicity and nausea associated with the use of
cisplatin, a first-generation platinum agent [8]. Cisplatin and CPT form reactive intracellular
platinum complexes that bind to nucleophilic groups in DNA, producing both inter- and
intra-strand crosslinks that inhibit DNA replication, RNA transcription, and protein synthesis,
resulting in apoptosis [9]. In birds, several cases have been reported in which CPT was applied
to treat neoplastic disorders with variable outcome. Intraosseus (IO) administration of CPT (3
doses of 5 mg/kg BW, at 4 week intervals) showed to be successful to treat pancreatic duct ade-
nocarcinoma in a Green-winged macaw (Ara chloroptera) [10]. Furthermore, intravenous (IV)
CPT administration (4 doses of 8.5–15 mg/kg BW, at 4–5 weeks intervals) in a duck (Anas pla-
tyrhynchos) reduced the size of a Sertoli cell tumour by 25%, and improved the duck’s clinical
condition for 12 months [11]. IV administration of CPT (3 doses of 5 mg/kg, at 4 week inter-
vals) in a budgerigar (Melopsittacus undulatus) with a renal adenocarcinoma initially improved
the clinical condition of the bird. Nevertheless, after three months, the bird’s condition gradu-
ally deteriorated and the mass was again enlarged [12].
Despite the clinical application of CPT in different avian species, a suitable treatment proto-
col, based on pharmacokinetic (PK) data, is lacking. Only one study described the PK behaviour
of CPT in sulfur-crested cockatoos [13]. Since the myelosuppressive toxicity of CPT is dose-
dependent, and determined by the area under the plasma concentration-time curve (AUC),
there is an urgent need for therapeutic drug monitoring and data regarding the PK characteris-
tics of CPT in birds [13, 14]. Similar to other drugs such as non-steroidal anti-inflammatory
drugs (NSAIDs) and antibiotics, the PK can be significantly influenced by the biological specifics
of the avian species and order, therefore species-specific PK studies in birds are needed [15, 16].
Therefore the aims of present study were first, to develop and validate a sensitive and specific
liquid chromatography-tandemmass spectrometric (LC-MS/MS) method for quantification of
CPT in avian plasma. Secondly, to study the PK of CPT in a representative species of four differ-
ent avian orders, namely Galliformes, Anseriformes, Colombiformes and Psittaciformes. Thirdly,
to apply allometric scaling to evaluate whether the PK results can be extrapolated to other avian
species (e.g. cockatoos) and eventually to other animal species and humans.
Materials and Methods
Chemicals, products and reagents
CPT used for the birds (10 mg/mL water) was obtained from Hospira (Brussels, Belgium) and
the analytical standard of CPT used for the analytical experiments was obtained from Sigma-
Aldrich (Bornem, Belgium) and stored at 4°C. Water and acetonitrile (ACN) were of LC–MS
grade and obtained from Biosolve (Valkenswaard, the Netherlands). Glacial acetic acid was of
analytical grade and obtained from VWR (Leuven, Belgium).
Animal experiments
The PK studies were carried out in chickens (ISA Brown layer, Gallus gallus), ducks (Call
Duck, Anas platyrhynchos), pigeons (racing pigeon, Columbia livia forma domestica) and para-
keets (English budgerigar,Melopsittacus undulatus). CPT was administered to eight (four male
/ four female) chickens, ducks and pigeons with an average ± SD body weight (BW) of
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1909 ± 619 g, 756 ± 101 g and 470 ± 67 g, respectively, and twenty-eight (fourteen male / four-
teen female) parakeets with an average BW of 61 ± 8 g. All birds were clinically healthy and on
average one year old (range 9–13 months). Throughout one week acclimatisation period, ani-
mals were housed in group per species, and had ad libitum access to feed and drinking water.
Subsequently, eight hours before the start of the experiment, the animals were deprived of
feed. Birds were anaesthetised for 10 min with isoflurane (IsoFlo, Abbott Animal Health,
Waver, Belgium) and oxygen inhalation. Body temperature during anaesthesia was maintained
using a heat mat. CPT was administered IV in the vena cutanea ulnaris superficialis (wing
vein) at a dose of 5 mg/kg BW. This was performed by cannulating the vein in chickens, ducks
and pigeons with a 26-gauge IV catheter (Terumo versatus winged IV catheter 26G 0.64x19
mm, Terumo Europe, Leuven, Belgium). In parakeets, IV administration was performed via a
27-gauge cannula scalp vein set (Venoflux, 0.40x16 mm, tube 7 cm, Vygon, Brussels, Belgium).
CPT (Hospira, Brussels, Belgium) was diluted in 5% dextrose solution (5 mg CPT/mL for
chickens, ducks and pigeons, and 2.5 mg CPT/mL for parakeets) and was infused in the vein
over 3 min. After CPT administration the catheter or cannula was flushed by an equal volume
of 5% dextrose solution. Subsequently, the IV catheter or cannula was removed and anaesthesia
was terminated 6 min after the start of the carboplatin infusion.
Blood samples (0.5 mL in chickens and ducks and 0.2 mL in pigeons and parakeets) were
collected in heparinised tubes from the vena metatarsalis plantaris superficialis (chickens,
ducks and pigeons) or the vena jugularis (parakeets) before administration (t = 0) and at 3 min
(end of infusion), 5, 10, 20, 30, 45 min and 1, 2, 3, 4, 6, 8, 12 and 24 h after the start of the infu-
sion. The blood samples before administration and at 3 and 5 min after the start of the infusion
were taken during anaesthesia. In chickens, ducks and pigeons, blood was drawn at each sam-
pling point from each animal. For parakeets, a sparse sampling protocol was applied because of
the limited volume of blood that can be drawn from these birds. Therefore, all sampling points
were randomly allocated to different birds, with three sampling points per bird. Blood samples
were centrifuged (2851 x g, 10 min, 4°C) and plasma was stored at -70°C until analysis.
Ethics Statement
The animal experiment was approved by the Ethical Committee of the Faculty of Veterinary
Medicine and Bioscience Engineering of Ghent University (EC 2012/109).
Quantification of carboplatin in plasma
To 50–100 μL of plasma (depending on the bird species) were added 50–100 μL of water fol-
lowed by a vortex mixing and filtration step (Amicon Ultra 0.5 mL centrifugal filter, MWCO
30 kDa, Millipore, Brussels, Belgium). Next, samples were centrifuged (8751 x g, 30 min, 4°C)
and the filtrate was transferred to an autosampler vial before injection onto the LC-MS/MS
instrument.
The chromatographic system consisted of an Alliance type 2695 HPLC separations module
with column heater and cooling device (Waters, Milford, USA). Chromatographic separation
was achieved using a Hypersil Gold aQ C18 column (150 x 4.6 mm i.d., d.p.: 3.0 μm), in combi-
nation with a guard column of the same type, from ThermoFisher Scientific (Breda, The Nether-
lands). Mobile phase A was 0.1% acetic acid in water, while mobile phase B was ACN. A gradient
elution program was performed: 0–4 min: 99% A/1% B, 4–6 min: linear to 30% A, 6–7 min: 30%
A/70% B, 7–8 min: linear to 99% A, 8–12 min: 99% A/1% B. The flow rate was set at 0.7 mL/min.
The LC column effluent was pumped to a Quattro Ultima triple quadrupole mass spectrom-
eter (Waters, Altrincham, UK), equipped with an electrospray ionization (ESI) ion source,
operated in the positive ion mode. A splitter device was used to direct 50% of the LC effluent to
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the mass spectrometer and 50% to the waste. The instrument was tuned by direct infusion of a
1 μg CPT/mL working solution. The following parameters were retained for optimal CPT
detection: capillary voltage: 3 kV, cone voltage: 45 V, source temperature: 120°C, desolvation
temperature: 250°C, cone gas flow: 55 L/h, desolvation gas flow: 845 L/h.
Acquisition was performed in the selected reaction monitoring (SRM) mode. Following SRM
transitions were monitored and used for identification and quantification of CPT:m/z
372.0> 229.0 and 372.0> 293.9 (collision energy: 17 eV), respectively. Quantification was per-
formed with the MassLynx software v4.0 (Micromass), using the above mentioned product ions.
The method was validated for plasma from the four different avian species according to a
validation protocol previously described by [17]. A set of parameters that were in compliance
with the recommendations and guidelines defined by the European Community and with crite-
ria described in the literature, were evaluated [18–20]. These parameters encompassed linearity
(correlation coefficient, r, and goodness-of-fit coefficient, g), within- and between-run accuracy
and precision, limit of quantification (LOQ) and carry-over.
Pharmacokinetic analysis and allometric scaling
Non-compartmental PK analysis was performed using WinNonlin version 6.3 (Pharsight, St-
Louis, MI, USA). Following main PK parameters after IV administration were calculated for the
different avian species: area under the plasma concentration-time curve from time 0 to the last
sample point with values above the LOQ (AUC0-t), area under the plasma concentration-time
curve from time 0 to infinite (AUC0-inf), plasma concentration at time zero (C0), elimination
rate constant (ke), elimination half-life (T1/2el), volume of distribution (Vd) and total body clear-
ance (Cl). Allometric scaling was applied on T1/2el, Vd and Cl based on the following power
function [21]: Y = a.Wb, where Y is the value of the respective PK parameter, a is the coefficient
of the intercept of the trend line,W is the body weight and b is the slope of the trend line.
Statistical analysis
All PK parameters were compared between avian species and between genders within one spe-
cies with one-way ANOVA and a Student’s t-test, respectively (SPSS 21.0, IBM, USA). The
level of significance was set at 0.05.
Results
LC-MS/MS method
Due to the broad concentration range of CPT in plasma (between 20 and 50 000 ng/mL),
matrix-matched calibration graphs (1/x weighed) were quadratic and split in a low and high
concentration range. The method of external standardization was applied, since the analyte
(oxaliplatin) that was used for internal standardization during preliminary experiments had a
limited stability in extracted samples in contrast to CPT. As a consequence, the quantification
of CPT in plasma was impaired by applying the method of internal standardization. Good cor-
relation between analyte concentrations and detected responses was demonstrated for all
matrices and both concentration ranges, with r values ranging between 0.9985 and 0.9999 and
g values between 3.43 and 7.29% (S1 Table). The within- and between-run accuracy and preci-
sion were evaluated at minimally 3 concentration levels and fell within the acceptability ranges
(S2 Table). The LOQs were 20 ng/mL for chicken and duck, 50 ng/mL for pigeon and 100 ng/
mL for parakeets (S1 Table). No carry-over was present as there was no CPT detected in the
solvent sample injected after the highest calibrator.
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Plasma pharmacokinetic analysis and allometric scaling
All birds tolerated the anaesthetic procedure as well as the CPT infusion, and recovered with-
out complications. During the animal experiment, no clinical signs of CPT toxicity were
observed in any of the birds. All birds were alert, had a normal feed intake and normal drop-
pings, and no vomiting was observed.
The plasma concentration-time profile and the main PK characteristics after IV administra-
tion of CPT to the different avian species are presented in Fig 1 and Table 1, respectively. There
were no significant gender differences within one species (results not shown). Between avian
species, significant differences were detected for AUC0-t, AUC0-inf, ke and T1/2el, but not for Vd
and Cl. Allometric scaling revealed a good correlation between T1/2el and BW of the bird spe-
cies (R²> 0.97), as depicted in Fig 2a. Furthermore, allometric scaling of the T1/2el was per-
formed in different avian species derived from this study and in all species for which literature
data are available, namely rat [22], cockatoo [13], cat [23], dog [24] and human [25]. Results
are presented in Fig 2b. A moderate correlation between T1/2el and BW of the different species
(R²> 0.82) was demonstrated.
Discussion
LC-MS/MS method
Several methods for detection of free CPT in biological fluids have been reported in literature.
In the last decade, LC-MS/MS became the method of choice due to its high sensitivity and
selectivity. It has been reported that sample treatment consisting of solid-phase extraction
(SPE), e.g. using C18, C2, CN and NH2 cartridges, generally leads to limited extraction recover-
ies [26]. CPT is a strong hydrophilic compound (log P = -2.3, chemical structure is shown in
Fig 1) [27] and cannot be retained on most reverse-phase SPE stationary phases, thus
Fig 1. Plasma concentration-time profiles of free carboplatin in different avian species (chicken, duck, pigeon and parakeet) after intravenous
administration of 5 mg carboplatin/kg body weight. Values are presented as mean + SD. The insert displays the chemical structure of carboplatin.
doi:10.1371/journal.pone.0134177.g001
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compromising the sensitivity and reproducibility of the method. In contrast, strong cation
exchange (SCX) columns contain benzenesulfonic acid anions which interact with the amine
groups on carboplatin, resulting in an adequate retention of CPT [28]. Nevertheless, these car-
tridges seem to be very sensitive to washing steps and elution volumes inducing variable extrac-
tion results [28]. On- and off-line protein precipitation has been described as sample
pretreatment procedure for human plasma, although significant matrix effect (signal suppres-
sion) was present yielding low analyte responses. The matrix effect was overcome by combin-
ing the precipitation of proteins with phospholipid removal (HybridSPE-PPT). However only
low extraction recoveries were obtained (range 0.1–32.4% depending on the solvent) [26]. For
PK studies where a large number of samples need to be analyzed, high-throughput sample
preparation is crucial. In the present study it was opted to dilute the sample by a factor 2, fol-
lowed by the physical removal of proteins and molecules with a molecular mass above 30 kDa
by ultrafiltration. This ultrafiltration is crucial as a fraction of the drug is unavailable because
of covalent binding to plasma proteins (accounting for 40% of the total CPT in humans [29]).
Therefore, only the free (unbound) fraction of CPT has to be quantified [30]. Chromatographic
separation of CPT is commonly performed by a combination of an organic solvent (ACN or
methanol) and water with a volatile acid (e.g. acetic acid or formic acid) [8]. The most optimal
chromatographic conditions were obtained by a combination of 0.1% acetic acid in water and
ACN. A Hypersil Gold aQ column was used as stationary phase for optimal retention of this
polar analyte. Concerning the MS/MS parameters, the highest sensitivity was obtained for the
protonated parent compound measured in the positive ESI mode and the followed SRM traces
were in accordance with literature [26, 31].
Pharmacokinetic analysis and allometric scaling
The dose used in this PK study (5 mg/kg BW) was based on a previous study in cockatoos [13].
Dosing of antineoplastic drugs should be done very carefully because of their narrow therapeu-
tic-toxic range. Chemotherapeutics are commonly dosed based on the body surface area (BSA)
of a patient instead of the BW, because the BSA is considered to be a better indicator of the
metabolic mass. However, limited information is available to determine the BSA in exotic ani-
mals such as pet birds [32]. Therefore, a major goal of this study was to determine whether
dose extrapolation between different avian species can be performed based on the correlation
Table 1. Main pharmacokinetic parameters of free carboplatin after intravenous administration (5 mg/kg BW) to chickens, ducks, pigeons and
parakeets.
Chicken Duck Pigeon Parakeet
AUC0-t (h.μg/mL) 17.43 ± 3.39
a 16.68 ± 2.79 a,b 11.21 ± 2.81 b 14.20 ± 1.73 a,b
AUC0-inf (h.μg/mL) 17.87 ± 3.52
a 16.76 ± 2.81 a,b 11.36 ± 2.78 b 14.31 ± 1.72 a,b
C0 (μg/mL) 41.27 ± 12.59
a 69.67 ± 24.55 a 32.91 ± 22.26 a 52.69 ± 40.59 a
ke (1/h) 0.63 ± 0.13
a 0.80 ± 0.14 a,b 1.04 ± 0.11 b 1.71 ± 0.22 c
T1/2el (h) 1.16 ± 0.22
a 0.90 ± 0.15 a,b 0.68 ± 0.07 b 0.41 ± 0.05 c
Vd (mL/kg) 494.82 ± 124.18 a 398.25 ± 72.75 a 517.45 ± 188.25 a 213.32 ± 35.39 a
Cl (mL/h/kg) 293.24 ± 62.17 a 309.82 ± 53.02 a 520.59 ± 179.94 a 355.44 ± 41.87 a
Values are presented as mean ± SD.
AUC0-t: area under the plasma concentration-time curve from time 0 to the last sample point with values above the limit of quantiﬁcation, AUC0-inf: area
under the plasma concentration-time curve from time 0 to inﬁnite, C0: plasma concentration at time 0, ke: elimination rate constant, T1/2el: elimination half-
life, Vd: volume of distribution, Cl: total body clearance.
Values within one parameter with a different superscript are statistically different at p < 0.05.
doi:10.1371/journal.pone.0134177.t001
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of one or more PK characteristics and the BW. Attempts have previously been made to allome-
trically scale the T1/2el with BW in birds for NSAIDs and antibiotics, however, with marginal
success. Reasons for this lack of correlation are still poorly understood but are thought to be
related to species dependent elimination processes and differences in protein binding [16]. In
our study, a clear correlation (R²> 0.97) was demonstrated between BW of the bird species
and T1/2el as depicted in Fig 2a and T1/2el ranged between 0.41 h for parakeets (average BW: 61
g) and 1.16 h for chickens (average BW: 1909 g) (Table 1). This indicates that, based on the
BW, the T1/2el can be estimated in avian species. Indeed, the T1/2el of ducks (average BW: 756
g), namely 0.90 h (Table 1), corresponds well with the previously described T1/2el in cockatoos
Fig 2. Allometric scaling of the elimination half-life of free carboplatin in different avian species
derived from the present study (a) and in all species for which literature data are available (b).
Elimination half-life values of rat, cockatoo, cat, dog and human were derived from [13, 22–25].
doi:10.1371/journal.pone.0134177.g002
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(average BW: 769 ± 68 g) of 1.00 h [13]. Furthermore, Siddik et al. [22], Bailey et al. [23], Gaver
et al. [24] and van der Vijgh [25] demonstrated a T1/2el of CPT in rats, cats, beagle dogs and
humans of 0.41, 1.31, 1 and 2 h, respectively [22–25], which could be scaled with an acceptable
correlation (R² = 0.83) as well (Fig 2b). However, it should be taken into account the use of dif-
ferent PK models can lead to slight differences in T1/2el as well. CPT in humans displays a
three-compartmental course, with a distribution (T1/2α = 0.38 h), initial (T1/2β = 2 h) and termi-
nal (T1/2γ = 5.8 days) elimination half-life [25]. Siddik et al. [22] applied a two-compartmental
model for CPT in rats (T1/2α = 0.036 h, T1/2β = 0.41 h), whereas in the present study in birds
and the other described studies in cockatoos [13], cats [23] and dogs [24] a non-compartmen-
tal model was used [13, 23, 24]. The values of T1/2el obtained from the non-compartmental
designs resemble the T1/2β from the two- or three-compartmental model as they are calculated
based on the last sampling points.
The results regarding T1/2el indicate that allometric scaling can most probably be applied
within one class, but it is not always applicable between classes. In accordance to the obtained
results in avian species, [33] allometrically scaled the PK characteristic of 44 drugs across veter-
inary and laboratory animal species and concluded that T1/2el is the most robust parameter for
interspecies scaling. In their study, the allometric exponent (b) averaged around 0.24 ± 0.09
with 65% of the b’s between 0.19 and 0.32. Indeed, the value most cited in literature in general
for this term is 0.25 [34]. These values correspond well with the value for b obtained in this
study, namely 0.30 within the four avian species studied and 0.25 within laboratory animals,
pets and humans. Next, it was also reported that although Cl and Vd might have a high intra-
and interspecies variability, the T1/2el can still remain stable [33]. In this respect, the Cl and Vd
had a low to moderate correlation in the present study, namely R² of 0.08 and 0.79, respectively
(data not shown). Despite the evidence that active renal secretion occurs in humans [35, 36],
CPT is mainly eliminated unchanged by the kidneys and therefore the T1/2el is primarily deter-
mined by the glomerular filtration rate (GFR). In human patients, the required dose is calcu-
lated by following formula [37]: dose (mg) = target AUC x (GFR + 25). In normally hydrated
birds, the whole kidney GFR (mL/h) can be scaled to the BW (g): Y = 1.24.W0.69 [38]. As the
exponent for scaling of GFR and T1/2el is different, 0.69 and 0.30, respectively, a similar formula
will probably not be accurate for dose determination in bird species. These differences can be
explained by species dependent differences in elimination of CPT. In rodents for instance, less
than 10% of CPT is eliminated through non-renal processes (bile or irreversible binding to
plasma proteins) [22], whereas in humans this is ± 30% [37]. As described above, active renal
secretion occurs in humans whilst in rodents CPT is renally excreted by glomerular filtration
alone [22]. Next, as only the free CPT can be eliminated, species dependent differences in
plasma protein binding can further explain the lack of correlation of GFR or clearance and the
BW of the species. Indeed, 4 and 24 h after administration of CPT to humans, only 24% and
40% of the CPT is bound to plasma proteins [29, 39], respectively, while in rats 65% of CPT is
bound after 4 h [22].
The demonstrated correlation between T1/2el and BW is a first step towards dose optimiza-
tion of CPT in avian species. An appropriate dosage regimen can be calculated based on PK
elimination data and the target CPT concentration for a certain type of tumour [37]. Although
CPT has been shown to be successful in different cases of avian oncology, e.g. pancreatic duct
adenocarcinoma [10], Sertoli cell tumour [11], and renal adenocarcinoma [12], measurements
of CPT target concentration are lacking. The CPT dose in this study was therefore adjusted
from the dose commonly used in chemotherapy in dogs [13]. Furthermore, dose optimization
should also include data about the maximum tolerated dose. No clinical signs of CPT toxicity
were observed in this trial, however blood counts or biochemistry were not evaluated since
only limited amount of blood could be collected and the total volume was needed for CPT
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analysis. In contrast, Filippich et al. [13] observed anorexia and vomiting in cockatoos subse-
quently to CPT administration at a dose of 5 mg/kg BW. However, myelosuppression, which is
the dose limiting side effect, has only been described in avian cases were CPT was administered
at multiple doses of 11.25–15 mg/kg BW [11, 40].
Conclusions
As a conclusion it can be stated that a sensitive and specific LC-MS/MS method was developed
for quantification of free CPT in avian plasma and that, based on the PK study performed in
parakeets, pigeons, ducks and chickens, the T1/2el of CPT seems to be the most robust parame-
ter for allometric scaling of CPT in avian species.
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